GLP-1 microdosing refers to using smaller-than-standard doses of GLP-1 medications, usually to reduce side effects while aiming for gradual weight or blood sugar changes. It's not an officially approved way to use these medications, so anyone considering it should talk with a doctor first.
Every report comes from a Lived member, sent anonymously.
Have you tried GLP-1 Microdosing for Prediabetes?
Microdosing a GLP-1 (glucagon-like peptide-1) medicine is the popular practice of taking semaglutide or tirzepatide at doses lower than their labels set for ongoing treatment. Semaglutide is the active ingredient in Ozempic, approved for type 2 diabetes, and Wegovy, approved for long-term weight management; tirzepatide is the equivalent in Mounjaro and Zepbound. People who microdose hope for appetite control with fewer side effects or at lower cost, often without close supervision. It is not an approved way to use these medicines. Each label begins with a low starting dose meant only for the first weeks, and the Zepbound label states that its 2.5 mg starting dose is not approved for maintenance. A prescriber slowing dose increases, or choosing a lower labeled maintenance dose such as Zepbound 5 mg, is different, and the labels allow both.
Both medicines mimic GLP-1, a hormone the gut releases after eating. They act on appetite pathways in the brain, slow stomach emptying and help the pancreas release insulin, so people feel full on less food. Microdosing assumes a smaller dose keeps part of that effect with less nausea. Lower doses are easier to tolerate, but whether a long-term low dose keeps enough benefit is not established. Research on microdosing itself is limited to reviews and health-record studies, and their authors call for proper trials. In an earlier trial comparing several semaglutide doses, lower doses produced less weight loss than higher ones.
Approved Wegovy and Zepbound pens are injected weekly and stepped up over several weeks to a maintenance dose. Microdoses are often drawn from compounded vials and measured in "units" on a syringe, or taken as a partial dose from a multi-dose pen, an amount no label describes. The Food and Drug Administration (FDA) has reports of people injecting 5 to 20 times the intended dose of compounded semaglutide after confusing units, milliliters and milligrams, some needing hospital care. Confirm the dose in milligrams and the exact syringe with the prescriber and pharmacist. Never share a multi-dose pen, even with a new needle, because it can spread blood-borne infections.
Nausea, diarrhea, constipation and stomach discomfort are the most common effects, and they tend to be milder at lower doses. A lower dose is still the same medicine, with the same serious label risks, including inflammation of the pancreas (pancreatitis) and gallbladder problems such as gallstones. Severe stomach pain that will not go away, sometimes spreading to the back, means stopping the medicine and contacting the prescriber right away, as does vomiting or diarrhea that does not settle. If too much was injected, call Poison Control at 1-800-222-1222 right away.
Both medicines carry a boxed warning, the FDA's most prominent label warning, because they caused thyroid tumors in rodents. People with a personal or family history of medullary thyroid cancer, or with multiple endocrine neoplasia type 2 (an inherited tumor syndrome), should not use them at any dose. Compounded versions are not reviewed by the FDA for safety, effectiveness or quality, and counterfeit pens and products sold online or as "research use only" may contain the wrong amount or harmful ingredients. With insulin or a sulfonylurea (a diabetes pill that boosts insulin release), these medicines raise the risk of low blood sugar. Both may harm an unborn baby; the Wegovy label advises stopping semaglutide at least two months before a planned pregnancy.
People who microdose often report a smaller appetite with fewer stomach effects, but these are personal accounts, not measured results. Weight loss is likely to be smaller than at labeled doses, and years at a low dose have not been studied. It helps to agree with a prescriber on what to track, such as weight, blood sugar or side effects, and when to reconsider.
Last reviewed • Oct 2026
Educational content, not medical advice.
I have been pre-diabetic for many years and would love to try a GLP1 but I have heard about so many people experiencing heavy hair loss. Does anyone have an information in this area?
Are there possibly any cheaper GLP-1s that insurance would possibly cover?
Doing GLP-1 Microdosing seems to be better for my health journey.